From: Efficacy and safety of i.v. sodium benzoate in urea cycle disorders: a multicentre retrospective study
Age category
Patients
N = 61 (%)
0–27 days
25 (26.3 %)
1-23 months
14 (14.7 %)
2–11 years
40 (42.1 %)
12–17 years
10 (10.5 %)
≥18 years
6 (6.3 %)